Indevus Gains Supprelin LA With Purchase Of Valera
This article was originally published in The Pink Sheet Daily
Executive Summary
Indevus also expects to out-license Valera's early stage pipeline, as well as several of its own products.
You may also be interested in...
Indevus’ Valstar Is “Approvable” At FDA
Agency seeks clarification of manufacturing validation protocols described in the firm’s sNDA for the bladder cancer treatment.
Indevus’ Valstar Is “Approvable” At FDA
Agency seeks clarification of manufacturing validation protocols described in the firm’s sNDA for the bladder cancer treatment.
Indevus Gains Sanctura XR Approval
The molecule’s “highly differentiated profile” will set it apart from others in the crowded urinary incontinence space, Indevus tells “The Pink Sheet” DAILY.